Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022
5.7.2022 12:14:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Center (DERC), will organize the upcoming edition of GLOBALEM, a definitive high power electromagnetic (HPEM) conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005033/en/
Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022 (photo: AETOSWire)
Set to run from November 13 to 17 at St. Regis Abu Dhabi, the conference marks the first high-profile event DERC is hosting after the launch of its prequalification testing facility at Tawazun Industrial Park in Abu Dhabi dedicated to a specific high-energy physics domain.
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center, will offer expertise as General Chair of the organizing committee of GLOBALEM. Other expert members include Dr. Bill Radasky, of Metatech Corporation USA, and Dr. Nicolas Mora from DERC as joint Technical Program Committee co-chairs, as well as Dr. Felix Vega from DERC, Dr. Lars Ole Fichte from the Helmut-Schmidt University in Hamburg, Germany, and Dr. Jane Lehr, from the University of New Mexico, USA, as conference advisors.
Unpacking the challenges and opportunities that currently exist as well as those evolving everyday in the crucial field of electromagnetics, the conference is set to draw the interest of experts from fields as diverse as pulsed power technologies, high voltage generator, microwaveradiation, covering analytical and numerical modeling as well as experimental validation
All eyes will be trained on the Best Student Paper Award (BSPA), with award recipients receiving a certificate and a cash prize of US$500.
Likewise, the Young Scientist Award (YSA) recognizes a young researcher under 35 who has made innovative contributions in fields related to HPEM. Researchers keen to participate in the contest can nominate themselves during the submission process.
For both awards, the last date for the submission of extended abstracts online is July 1, 2022. Acceptance confirmations and nominations will be completed by August 15, and September 15 is the last date for the final review and submission of full papers and award nominations. Early bird registration is open until September 30, 2022.
Highlighting the significance of the conference for the TII ecosystem and for Abu Dhabi as well, Dr. Kasmi said: “The GLOBALEM conference promises to be a game changer for the region. High Power Electromagnetics is one of those hot areas in focus today for us at DERC, given the varied number of applications and sectors it straddles – from your everyday generators, motors, and transformers, to maglev trains, and astronomy to health care and everything in between. We are even focusing on new innovations that can treat certain types of cancer. Being able to convene so many global experts in Abu Dhabi is unprecedented and is a big deal for TII and the region.”
For more information on the GLOBALEM Conference 2022, and to submit scientific papers please visit: https://globalem2022.com/submission.php
About the Technology Innovation Institute (TII)
The Technology Innovation Institute (TII) is the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), and a leading global scientific research center that focuses on shaping breakthrough solutions and new-age technology capabilities. In working with exceptional talent, universities, research institutions and industry partners from around the world, TII connects an intellectual community and contributes to building a thriving R&D ecosystem that elevates the status of Abu Dhabi and the UAE as a global hub for innovation. For more information, please visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005033/en/
Contact information
Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom